Guangzhou Sinohealth Information: Chapter One of "China Innovative Drug Blue Paper (2025)" Report

Since the State Council released the "Opinions on Reforming the Review and Approval System for Drugs and Medical Devices" ("Document 44") in 2015, China's innovative drug industry has undergone a profound strategic transformation and systematic restructuring, achieving a historic leap from being "dominated by generics" to "innovation-led." Over the past decade, driven by policy incentives, market demand, capital investment, and technological innovation, China has successfully built an innovative drug industry ecosystem that covers the entire chain of R&D, review, payment, and application.